Dr. John Anderson -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. John Anderson, a Ophthalmology physician based in City, VA. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. John Anderson has received $6,611.64 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. John Anderson
- Medical Specialty: Ophthalmology
- Practice Location: City, VA, Virginia
- NPI Number: 1906347688
- Transparency Score: 75/100
- Payment Records Span: 2026-03-05 to 2026-03-05
Payment Summary
Dr. John Anderson has received a total of $6,611.64 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $6,611.64 per transaction.
- Total Payments Received: $6,611.64
- Number of Transactions: 1
- Average Payment: $6,611.64
- Transparency Score: 75/100 -- This score reflects the overall payment profile relative to peers in Ophthalmology. A higher score indicates fewer or more routine payments.
- Number of Pharma Relationships: 1 pharmaceutical companies
- Drugs/Devices Referenced: 1 distinct products
Payment Breakdown by Category
The following table shows how Dr. John Anderson's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|---|---|
| Consulting Fees | $6,611.64 | Advisory board participation, clinical consulting, and expert opinion services |
The largest payment category for Dr. John Anderson is Consulting Fees, accounting for 100% ($6,611.64) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. John Anderson. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| Bayer Healthcare | $6,611.64 | 1 |
Dr. John Anderson has a financial relationship with Bayer Healthcare, receiving $6,611.64 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
Drugs and Medical Devices Referenced in Payments
The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. John Anderson. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.
- Biktarvy -- Referenced in payment records from pharmaceutical companies to Dr. John Anderson
The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.
AI Transparency Analysis
The following analysis was generated by artificial intelligence based on Dr. John Anderson's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.
John Anderson has received $6.6K across 1 pharmaceutical payments as a Ophthalmology physician in City, VA. Top paying companies include Bayer Healthcare ($6.6K). Dr. Anderson received a single payment of $6,612 in 2026, indicating a recent engagement. The entire payment came from Bayer Healthcare, suggesting a strong relationship with this single company. This payment was categorized as 'consulting', providing insight into the nature of the engagement.
Patient Guidance: Questions to Ask Your Doctor
If Dr. John Anderson is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:
Patients may wish to inquire about any potential conflicts of interest or how industry relationships might influence treatment recommendations. Always feel free to ask your doctor directly about their pharmaceutical relationships.
Peer Comparison: How Dr. John Anderson Compares to Other Ophthalmology Physicians
For an Ophthalmologist, receiving a single, large consulting payment from a pharmaceutical company is not uncommon, especially for specialized advisory roles.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. John Anderson in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| Bayer Healthcare | $6,611.64 | consulting | Biktarvy | 2026-03-05 | Not Assessed |
Frequently Asked Questions About Dr. John Anderson's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
How much pharma money has John Anderson received?
John Anderson has received a total of $6.6K across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.
Is John Anderson taking too much pharma money?
John Anderson has received $6.6K in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Ophthalmology), the types of payments, and how they compare to peers. The largest payment category is consulting ($6.6K). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.
What pharma companies pay John Anderson?
The top pharmaceutical companies paying John Anderson are: Bayer Healthcare ($6.6K). These payments cover various categories including consulting, meals, speaking fees, and research grants.
What kinds of payments does John Anderson receive?
John Anderson's payments by type: consulting: $6.6K. Consulting fees suggest active advisory roles with pharmaceutical companies.
Should I switch doctors because of pharma payments?
Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.
How do John Anderson's payments compare to other Ophthalmology doctors?
To compare, look at the total amount ($6.6K), number of payments (1), and the types of payments received. Ophthalmology physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.
How can I verify John Anderson's payment data?
You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1906347688). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.
Do pharma payments affect prescribing quality?
Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.
What stands out about John Anderson's pharma payment profile?
The doctor's payment profile is highly concentrated with 100% of the total amount coming from one company (Bayer Healthcare). John Anderson has received $6.6K in total pharma payments.
How does John Anderson compare to peers in Ophthalmology?
For an Ophthalmologist, receiving a single, large consulting payment from a pharmaceutical company is not uncommon, especially for specialized advisory roles.
Are John Anderson's pharma relationships typical for Ophthalmology?
The single payment received is substantial ($6,612), suggesting a significant consulting role or project.
What should patients of John Anderson know about these payments?
Patients may wish to inquire about any potential conflicts of interest or how industry relationships might influence treatment recommendations.
What patterns are visible in John Anderson's payment history?
The data indicates a single payment event in 2026, which might represent a new or isolated interaction.
Understanding This Doctor Payment Report
This transparency report for Dr. John Anderson is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. Ophthalmology physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. John Anderson's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. John Anderson and all other physicians can be accessed at the official CMS Open Payments website.
Related Resources
- Ophthalmology Specialty Payment Data -- See payment patterns for all ophthalmology physicians
- Virginia Physician Payments -- Browse pharmaceutical payments to physicians in Virginia
- Ophthalmology Physicians in Virginia -- Compare Dr. John Anderson to peers in the same state and specialty
- Bayer Healthcare Payment Profile -- View all payments made by Dr. John Anderson's largest pharmaceutical partner
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. John Anderson's NPI (1906347688) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.